New Zealand Becomes First Major Country to Ban Vaginal Mesh Implants

New Zealand Becomes First Major Country to Ban Vaginal Mesh Implants

New Zealand has become the first major country to effectively ban surgical mesh implants for all pelvic operations in response to safety concerns and reported mesh hazards. The order from the country’s Ministry of Health is intended to force mesh suppliers to stop marketing the mesh products or prove that they are safe to use. [Read more…]

Johnson & Johnson Pays $120 Million Settlement in Surgical Mesh Lawsuit

Johnson & Johnson $120 Million Settlement in Surgical Mesh Lawsuit

Medical device manufacturer Johnson & Johnson (J&J) has agreed to pay a $120 million settlement to the 2-3,000 women who filed injury lawsuits claiming to have suffered organ damage and constant pain from allegedly dangerous and defective surgical mesh. As reported by Bloomberg, these “settlements mark the first time J&J and its Ethicon unit have agreed to resolve a significant number of mesh cases.” [Read more…]

FDA Classifies Transvaginal Mesh as High-Risk due to Serious Complications from Surgery

FDA Classifies Transvaginal Mesh As High Risk

The U.S. Food and Drug Administration (FDA) has reclassified the surgical mesh device utilized for transvaginal repair of pelvic organ prolapse (“POP”) and other conditions in women as a high-risk (class III) product. Previously, the agency classified the product as moderate-risk (class II). [Read more…]

Pelvic Mesh Trial News

Image: courthouse - Pelvic Mesh Trial News

Thousands of injured women nationwide have filed lawsuits in state and federal courts against manufacturers of surgical pelvic mesh implants, claiming that the design of the product was defective and led to serious side effects and permanent injuries. These serious health complications include vaginal mesh erosion, vaginal scarring, contraction or shrinking of the mesh, infection, bleeding, neuro-muscular problems, onset or resurgence of urinary problems, and severe pelvic discomfort and pain.

[Read more…]